NEW YORK, NY / ACCESSWIRE / January 9, 2018 / The Nasdaq and S&P 500 continued to hit new record highs Monday as investors appear to be encouraged by a strengthening U.S. economy and possible tax reform. The Dow hit a new intraday record before slipping into the red. The S&P 500 Index gained 0.17 percent to close at 2,747.71, while the Nasdaq Composite Index rose 0.29 percent to close at 7,157.39. The Dow Jones Industrial Average hit an intraday record of 25,311.99 before settling to close at 25,283.00, down 0.05 percent. The S&P 500 has now hit a new record close in every trading day in 2018, the longest streak since 1964.
"We're in a pretty good situation: the economy is doing great, everyone expects us to raise rates gradually ... and if the data change we can respond to that," said Fed President John Williams in an interview with Reuters.
RDI Initiates Coverage on:
Galectin Therapeutics Inc.
Hemispherx BioPharma, Inc.
Galectin Therapeutics stock jumped 21.98% Monday, to close the day at $5.05. The stock recorded a trading volume of 1,859,715 shares, which was above its three months average volume of 751,798 shares. In the last year, Galectin Therapeutics shares have traded in a range of 0.94 - 5.12. The share price has gained 437.23% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $2.68 is greater than its 200-day moving average of $2.32. Shares of Galectin Therapeutics have gained roughly 107.82 percent in the past month and are down 51.2 percent year-to-date.
Access RDI's Galectin Therapeutics Inc. Research Report at:
On Monday, shares of Hemispherx BioPharma, Inc. recorded a trading volume of 4,727,679 shares, which was above the three months average volume of 441,062 shares. The stock ended the day 19.82% higher at 0.43. The share price has gained 44.67% from its 52 week low with a 52 week trading range of 0.30 - 0.93.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.34 is below its 200-day moving average of $0.37. Shares of Hemispherx BioPharma have gained roughly 19.72 percent in the past month and are up 25.43 percent year-to-date.
Access RDI's Hemispherx BioPharma, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.